This is an expanded access program (EAP) for eligible patients with Recurrent Ovarian Cancer.
This program is designed to provide access to niraparib prior to approval by the US Food and
Drug Administration (FDA).
To be eligible, patients with Recurrent Ovarian Cancer following a partial (PR) or complete
response (CR) to their most recent platinum-based chemotherapy and must have experienced a PR
or CR after the penultimate (next to last) platinum-based chemotherapy for at least 6 months
without disease progression after this chemotherapy.